보로노이

310210KOSDAQ

50.3 / 100

Reference Date: 2026-09-08

Financial Score14.0 / 40

News Sentiment18.3 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Rose 5.4% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Boronoai is a biotech company specializing in the development of targeted therapies for cancers such as lung and breast cancer, leveraging its in-house research facilities and AI platforms to conduct early clinical trials and pursue a global licensing-out (License-Out) business model. The company focuses on kinase inhibitors, leveraging its expertise and accelerated development timelines to build competitive pipelines.

Number of Employees

149people

Average Salary

81.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

—Industry Average 1.203.5Point

ROE

-50.18Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

57.37Industry Average 100.005.0Point

Lower than industry avg (good)

Trend 2023~20251.5 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

0.0 / 3

Avg ▼32.8% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -52.7% (improving, 3yr)

Detailed News Sentiment

9 totalPositive 6Neutral 1Negative 2Average Sentiment Score 73.3

Neutral
문명 7, 신규 업데이트 '내일의 궤적'과 원자 시대 예고
Positive
보로노이, 폐암 신약 고용량 도전
보로노이의 VRN11 고용량 투여 시험 확대는 폐암 신약 개발의 진전을 보여주며 시장 경쟁력 강화에 기여할 것으로 기대된다.
Positive
코스피, 美증시 훈풍에 올라 6,600대…코스닥도 닷새만 상승(종합)
코스피 상승과 함께 보로노이의 주가도 외국인과 기관의 매수 증가로 긍정적 영향을 받고 있다.

Detailed Momentum

52-week position3.0Point

52w lower range (20%)

Current 155,700Won52-week high 363,50052-week low 100,800

1-month return4.0Point

1m +5.42% (slight rise)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

6 totalPositive 0Neutral 6Negative 0

Neutral[기재정정]투자판단관련주요경영사항(임상시험계획변경승인) (VRN110755의 제 1/2상 임상시험)2026-09-07
Neutral주식등의대량보유상황보고서(일반)2026-08-31
Neutral주식등의대량보유상황보고서(일반)2026-08-28
Neutral기업설명회(IR)개최2026-08-21
Neutral[기재정정]투자판단관련주요경영사항(임상시험계획변경승인) (VRN110755의 제 1/2상 임상시험)2026-08-18